Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 2/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.61 |
| ▸ | PRKDC | P78527 | 1/20 | 0.61 |
| ▸ | IGF1R | P08069 | 12/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | JAK3 | P52333 | 1/20 | 0.55 |
| ▸ | INSR | P06213 | 5/20 | 0.52 |
| ▸ | LYN | P07948 | 4/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.52 |
| ▸ | LCK | P06239 | 3/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.52 |
| ▸ | FLT4 | P35916 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | FLT3 | P36888 | 3/20 | 0.52 |
| ▸ | SRC | P12931 | 3/20 | 0.52 |
| ▸ | STK3 | Q13188 | 3/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15032652 | 0.88 | JAK3 (0.63) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL6871843 | 0.87 | PRMT5 (0.57) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL12438016 | 0.84 | IGF1R (0.51) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL14115599 | 0.83 | PIK3CG (0.52) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL7013879 | 0.82 | LRRK2 (0.65) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL17731204 | 0.81 | PIK3CD (0.57) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL7021288 | 0.79 | LRRK2 (0.63) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL21048477 | 0.79 | PIK3CD (0.67) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL6634899 | 0.78 | BTK (0.47) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL12438584 | 0.77 | LRRK2 (0.55) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009070328-A1 | MODULATORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) PATHWAY FOR USE IN THE TREATMENT OR PREVENTION OF SUBSTANCE ABUSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-04 | — | — | WO | disclosed |
| US-7326699-B2 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | NOVARTIS AG (CH) | 2008-02-05 | — | — | US | disclosed |
| US-20060058324-A1 | 4-Amino-5-phenyl-7-cyclohexyl-pyrrolo 2,3-d pyrimidine derivatives | CAPRARO HANS-GEORG | 2006-03-16 | — | — | US | disclosed |
| EP-1390369-B1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| EP-1562947-A1 | 4-AMINO-5-PHENYL-7-CYCLOHEXYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2005-08-17 | — | — | EP | disclosed |
| US-20040180911-A1 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
| WO-2004043962-A1 | 4-AMINO-5-PHENYL-7-CYCLOHEXYL-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2004-05-27 | — | — | WO | disclosed |
| EP-1390369-A1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2004-02-25 | — | — | EP | disclosed |
| EP-0888353-B1 | N-7-HETEROCYCLYL PYRROLO [2,3-d]PYRIMIDINES AND THEIR USE | NOVARTIS AG (CH) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002092599-A1 | 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PYRROLO (2,3-D) PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | disclosed |
| US-6051577-A | TYROSINE INHIBITORS; BONE DISORDERS | NOVARTIS AG (CH) | 2000-04-18 | — | — | US | disclosed |
| EP-0888353-A1 | NOVEL N-7-HETEROCYCLYL PYRROLO 2,3-D]PYRIDINES AND THEIR USE | Novartis AG (CH) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034895-A1 | NOVEL N-7-HETEROCYCLYL PYRROLO[2,3-D]PYRIDINES AND THEIR USE | NOVARTIS AG (CH) | 1997-09-25 | — | — | WO | disclosed |
| WO-1997032879-A1 | 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINES | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | disclosed |
| WO-1997028161-A1 | NOVEL PYRROLO[2,3-D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058324-A1 | 4-Amino-5-phenyl-7-cyclohexyl-pyrrolo 2,3-d pyrimidine derivatives | TYMP, TYMS, APRT | PIK3CG 414/4885PIK3CD 271/4885PIK3CA 88/4885 |
| US-20040180911-A1 | 4-Amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives | TYMP, DPYD, TYMS | PIK3CG 623/4885PIK3CD 427/4885PIK3CA 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.